rawfin.tv
BofA Raises Peak Sales Estimate for J&J's Icotyde to $4.5 Billion
MarketsstocksAI Generated

BofA Raises Peak Sales Estimate for J&J's Icotyde to $4.5 Billion

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Bank of America has increased its peak sales forecast for Johnson & Johnson's oral psoriasis drug, Icotyde, to $4.5 billion. This revised estimate reflects strong market potential for the pharmaceutical product.

PharmaceuticalsDrug SalesAnalyst RatingsJNJ

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks